

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		09211297	
	Filing Date		1998-12-14	
	First Named Inventor	Boyle, William J.		
	Art Unit	1644		
	Examiner Name	Szperka, Michael E.		
	Attorney Docket Number	A-451M IDS#2-101408		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9626217	WO	A1	1996-08-29	Goto et al. (English Equivalent EP 0 816 380 A1)		<input type="checkbox"/>
	2	9700318	WO	A1	1997-01-03	Roodman		<input type="checkbox"/>
	3	9807840	WO	A1	1998-02-26	Nakagawa et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		09211297
Filing Date		1998-12-14
First Named Inventor	Boyle, William J.	
Art Unit	1644	
Examiner Name	Szperka, Michael E.	
Attorney Docket Number	A-451M IDS#2-101408	

	4	9846644	WO	A1	1998-10-22	Yamaguchi et al.		<input type="checkbox"/>
	5	9846751	WO	A1	1998-10-22	Boyle		<input type="checkbox"/>
	6	9849305	WO	A1	1998-11-05	Boyle et al.		<input type="checkbox"/>
	7	0874045	EP	A1	1998-10-28	Nakagawa et al.		<input type="checkbox"/>
	8	0117543	WO	A2	2001-03-15	Dunstan		<input type="checkbox"/>
	9	0117543	WO	A3	2001-03-15	Dunstan		<input type="checkbox"/>
	10	0118203	WO	A1	2001-03-15	Dunstan et al.		<input type="checkbox"/>
	11	0216551	WO	A2	2002-02-28	Choi et al.		<input type="checkbox"/>
	12	0216551	WO	A3	2002-02-28	Choi et al.		<input type="checkbox"/>
	13	03002713	WO	A2	2003-01-09	Boyle et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

**NON-PATENT LITERATURE DOCUMENTS**

Remove

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09211297
Filing Date	1998-12-14
First Named Inventor	Boyle, William J.
Art Unit	1644
Examiner Name	Szperka, Michael E.
Attorney Docket Number	A-451M IDS#2-101408

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	O'Brien, E. A. et al., "Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria", Biochem. Biophys. Res. Commun., 274: 281-290 (2000)	<input type="checkbox"/>
	2	Oyajobi et al., "Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa-B-igG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hyperclacemia of malignancy", Cancer Res., 61: 2572-2578 (March 15, 2001)	<input type="checkbox"/>
	3	Peterson et al., "AMG162, A fully human monoclonal antibody against receptor activator of NF-Kappa B ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey", Internatl. Bone and Mineral Society-Japan Bone and Mineral Society, 2003, Poster Session 2 "Osteoclasts", Osaka, Japan (June 6, 2003)	<input type="checkbox"/>
	4	Reddi, A. H., "Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state", Cell, 89: 151-161 (1997)	<input type="checkbox"/>
	5	Reiger et al., Glossary of Genetics and Cytogenetics, p. 17, Springer-Verlag Berlin Heidelberg, New York (1976)	<input type="checkbox"/>
	6	Suda, T. et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocr. Rev., 20: 345-357 (1999)	<input type="checkbox"/>
	7	Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", Bone and Mineral, 17: 347-359 (1992)	<input type="checkbox"/>
	8	Takeyama, S. et al., "Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor", Biochim. Biophys. Res. Commun., 276: 524-529 (2000)	<input type="checkbox"/>
	9	Teng, Y. A. et al., "Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection", J. Clin. Invest., 106: 749-752 (2000)	<input type="checkbox"/>
	10	Tsuda et al., "Isolation of a novel cutokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, 234(1): 137-142 (1997)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09211297
Filing Date	1998-12-14
First Named Inventor	Boyle, William J.
Art Unit	1644
Examiner Name	Szperka, Michael E.
Attorney Docket Number	A-451M IDS#2-101408

11	Udagawa, N. et al., "Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but no macrophage colony-stimulating factors", Bone, 25: 517-523 (1999)	<input type="checkbox"/>
12	Watanabe et al., "Interlukin-4 as a potent inhibitor of bone resorption", Biochemical and Biophysical Research Communications, 172(3): 1035-141 (1990)	<input type="checkbox"/>
13	Willard, D. et al., "Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain", Protein Expr. Purif., 20: 48-57 (2000)	<input type="checkbox"/>
14	Wong et al., J. Biol. Chem. "The TRAF Family of Signal Transducers Mediates NF-kB Activation by the TRANCE Receptor", 273(43): 28355-28359 (1998)	<input type="checkbox"/>
15	Yoneda et al., "Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer", Cancer Research, 55: 1989-1993 (1995)	<input type="checkbox"/>
16	Zhang et al., "Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways", J. Biol. Chem., 276(1): 563-568 (January 5, 2001)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.